Recorded Webinar: Reducing Cell Therapy Release Assay Time from Days to Seconds with AI


Reducing Cell Therapy Release Assay Time from Days to Seconds with AI

Microscopic image analysis can quickly become a bottleneck in the development and manufacture of next-generation cell therapies. QA/QC imagery accumulates. AI-based release assays for CT manufacturing can help quality teams to release batches faster, and with better information such as with the percentage of viable cells, location of dead cells, or even the identity of specific cell types without staining.

In this recorded webinar, the Likarda team and our guest Dr. Bruno Chilian, CSO from Thinking Research Instruments (TRI) discuss:

  • the benefits of implementing artificial intelligence to assist microscopy analyses
  • the readiness of reliable release assays for cell therapy manufacturing
  • the  steps quality and manufacturing teams can take to get reproducible QA/QC results  while increasing time and cost savings 

See how artificial intelligence can free your developmental and manufacturing workflows for cell-based therapies by accessing our recording today.

Meet the Speakers

Lisa Stehno-Bittel, PhD

President and Founder

Dr. Stehno-Bittel is founder of Likarda and serves as the President. She launched the company over seven years ago based on her extensive research and built a dedicated team of scientists at Likarda that advance the science and technology of CSS  drug delivery and logistical optimization for cell therapy and biologics. That innovative spirit continues with numerous new inventions and awards including Ingram’s Magazine’s “50 Kansans You Should Know” and the Women in Medicine and Science Sirridge award for female role models. Most recently the Women We Admire Organization named Stehno-Bittel one of the Top 50 Women Leaders in the state.

Stephen Harrington, PhD

Director of Hydrogel and Cell Formulation

Dr. Stephen Harrington is an innovative biomaterials engineer specializing in the use of hydrogels for cell therapy and other biomedical applications. Dr. Harrington is the Head of Hydrogel and Cell Formulation at Likarda, LLC and is the inventor of its patented Core-Shell Spherification Technology. Stephen earned his PhD in biomaterials and tissue engineering at the University of Kansas in 2017 under the mentorship of Likarda’s President and Founder, Lisa Stehno-Bittel. Dr. Harrington’s graduate research focused on the use of novel hydrogel microspheres for islet transplantation his work with Likarda has advanced the application of hydrogels into numerous other areas including osteoarthritis, liver disease, CAR-T cell therapy, biologics delivery, and cryopreservation.

Bruno Chilian, PhD

Thinking Research Instruments (TRI)

Dr. Bruno Chilian studied Physics in Hamburg, Germany and spent several years in the Pharma and Biotech industry before co-founding TRI Thinking Research Instruments GmbH. The recurring theme in his career is microscopy and automated image analysis. He shares the passion for machine-learning approaches with his university friend Johannes Bauer, who is a computer- and data-scientist. Over the course of many evenings of discussions, the two developed the idea of a system for imaging and analysis that feels almost like a partner to the biologist and complements their skills by enabling state-of-the-art AI tools to be applied directly to biological problems without the need for special training.

About Likarda

Likarda is a leading biotech company specializing in the development of enabling technologies for the delivery of both cell therapies and large molecule biologics. These advancements aim to enhance therapeutic efficacy and offer patients a sustainable solution for their chronic or life-threatening diseases. At the heart of Likarda’s innovation is the Core-Shell Spherification (CSS) technology. This revolutionary approach coats cells and biologics with inert hydrogels, ensuring they remain at their intended target location within the body and are shielded from potential degradation. This customizable platform is pivotal in maintaining cell viability and optimizing the delivery of biologics. For more insights, visit

About Thinking Research Instruments (TRI)

TRI is dedicated to bringing sophisticated AI-based image analysis to the lab. We give researchers and practitioners in the biomedical fields solutions built around state-of-the art machine learning algorithms. With these systems, users can analyze their data with the same sophistication with which they produced them. TRI’s flagship product, VAIDR, integrates image acquisition, data management, and AI-based image analysis. It can be used on-premise, where it integrates with the proprietary automated VAIDR microscope, or online, where images from any source can be uploaded and subsequently analyzed.

Submit the form below to access the recorded webinar

We’re here to help you improve the efficacy of your cell therapies and invite you to follow us on social media for the latest updates.